Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026

Core Insights - Nicox SA will present phase 3 clinical study results for NCX 470 at the American Glaucoma Society (AGS) Annual Meeting 2026, highlighting the product's medical effectiveness [1][2] - The presentations will include two podium sessions focusing on the efficacy, safety, and mechanism of action of NCX 470, which is a nitric oxide-donating bimatoprost eye drop [2][3] Company Overview - Nicox is an international ophthalmology company focused on innovative solutions for ocular health, with NCX 470 as its lead late-stage development program [5] - The company has licensing agreements for NCX 470 with Kowa for global markets and Ocumension Therapeutics for China, Korea, and Southeast Asia [5] - Nicox also has a preclinical program for NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, and generates revenue from its product ZERVIATE® for allergic conjunctivitis [5] Presentation Details - The AGS 2026 Annual Meeting will take place from February 19 to February 22, 2026, in Rancho Mirage, CA, U.S. [3] - Key presentations include: - "A Randomized Trial Comparing NCX 470 0.1% and Latanoprost 0.005% for Open-Angle Glaucoma" by Dr. S. Asrani on February 20, 2026 [3] - "Aqueous Humor Dynamics of NCX 470" by Dr. A. Sit on February 20, 2026 [3] - "Outcomes in the United States Subgroup of the Denali Trial" [3]